Experimental Alzheimer's drug shows benefits in phase 3 trial, company says

  • 📰 NBCNewsHealth
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 51%

United States News News

United States United States Latest News,United States United States Headlines

Japanese drugmaker Eisai said cognitive function slowed over 18 months in patients who received the drug, called lecanemab.

BSIP / UIG via Getty ImagesThe Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness.

Dr. Alberto Espay, a neurologist at the University of Cincinnati College of Medicine, said that the benefit was"small" and that it fell below the threshold of what would be meaningful to a patient. Still, he said,"patients can view this with cautious optimism."

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Can't wait for the one for cancer. You know the disease that insurance companies and hospitals make most their money on. Oh, wait the key word is money. So, no time soon for that one!

I know we all probably might have heard about Bitcoin but don't know how it works, I tried it in a week ago by a man who recommended me to Samantha_M078 on Twitter he guides me through and i made a return of $10500 after a week of trading, connect with her

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 707. in US

United States United States Latest News, United States United States Headlines